Table of Contents Table of Contents
Previous Page  32 / 398 Next Page
Information
Show Menu
Previous Page 32 / 398 Next Page
Page Background

Abstracts

27

have here their limitation and are for such reconstruction until

today not an alternative due to their poor regeneration potential.

Autogenous bone graft harvested from intraoral sites, espe-

cially the retromolar area of the mandible, and used following the

split bone block (SBB) technique is offering many possibilities for

intra operative facilities and stable long-term results. Splitting the

thick cortical block to 2 or 3 thin blocks is augmenting the num-

ber of blocks allowing the reconstruction of larger atrophic crest

and giving a better adaptation to the recipient site with individual

determination of the width and the volume of the grafted area. Fill-

ing the space and gaps between the thin block and the remaining

crest with particulate bone chips is reducing the time needed for

revascularisation of the graft improving its vitality compared to

the original thick block.

Many studies demonstrate that the reconstruction of horizontal

and vertical atrophied crest with thin mandibular blocks in com-

bination with particulate bone grafts, without any biomaterial or

membrane, offer over years, through the high vitality of the grafted

and regenerated bone, a stable periimplant bone level.

15 years results on more of 1300 grafting procedure for

horizontal and vertical bone augmentation present a low compli-

cation rate and showed that changes of the volume of the grafted

bone occurred up to one year after the grafting procedures and

stays stable for more than 15 years. Limited bone resorptions

were observed, especially when the bone block was grafted out-

side the bone contours, but without negative influence on the

definitive treatment. Implants inserted in this grafted bone pre-

sented similar osseointegration as implants placed in non-grafted

bone.

http://dx.doi.org/10.1016/j.ijom.2017.02.099

Development of biodegradable future suture

S.G. Kim

Gangneung-Wonju National University, Gangwon-do, Republic

of Korea

Silk suture material is mainly composed of silk fibroin, which is

produced by silkworm

Bombyx mori.

Silk suture is regarded as

non-resorbable material and it is slowly degraded by proteolysis

when it is implanted into body. 4-Hexylresorcinol (4HR) is well

known antiseptics.

In this study, the biodegradability of the 4HR incorporated

silk suture was compared to those of untreated silk suture and

polyglactin 910 suture which is commercially available resorbable

suture. Silk fibroin disc contained 4HR showed anti-septic prop-

erty and this property was maintained after autoclaving. Matrix

metalloproteinase (MMP) can digest wide spectrum of protein

including collagens. 4HR increased MMP-2, -3, and -9 expression

in RAW264.7 cells. MMP-2, -3, and -9 could digest not only silk

fibroin but also silk suture in

in vitro

experiments. The inhibitor

of MMPs could prevent proteolysis of silk fibroin by MMPs. As

a consequence, 4HR incorporated silk suture was rapidly biode-

graded compared to untreated silk suture and with the similar rate

to polyglactin 910 in the animal model. Expression of MMP-2,

-3 and -9 was high in the 4HR incorporated silk suture implanted

site at 12 weeks after implantation.

In conclusion, 4HR-treated silk suture showed similar level of

bio-degradation to polyglactin 910 suture via higher expression of

MMP-2, -3, and -9 in macrophage.

http://dx.doi.org/10.1016/j.ijom.2017.02.100

Revised protocol for the management of medication-related

osteonecrosis of the jaw

S.J. Kim

Ewha Womans University, Seoul, Republic of Korea

Medication-related osteonecrosis of the jaw (MRONJ) has been

reported in patients undergoing treatment with bisphosphonates

for osteoporosis, and because of the 10-year half-life of bisphos-

phonates, there is a need for further studies of this extensive

population.

This presentation provides revised protocol based on several

case reports to show the contrast in treatment outcomes and mor-

bidity in patients with MRONJ. The cases involved diagnostic

imaging modalities commonly used in the practice of dentistry:

panoramic radiography and computed tomography and bone scan.

This case reports demonstrate the usefulness of dental diag-

nostic imaging in the detection and management of MRONJ,

corroborate the increasing number of reports regarding high lev-

els of morbidity associated with various MRONJ treatments, and

underscore the danger of performing invasive dental procedures

for patients receiving bisphosphonate therapy.

This report provides information on the high levels of morbid-

ity associated with various MRONJ treatments, and underscores

the danger of performing even simple procedures, such as

denture delivery for patients receiving bisphosphonate therapy.

Once osteonecrosis of the mandible begins, it is nearly impos-

sible to eradicate the condition. Exposed bone, the hallmark

of MRONJ, will remain and may even progress to fracture.

Therefore, prevention of infection and avoiding the need for

surgery form the cornerstone of treatment. To reach the exact

conclusion, long-term follow-up studies and systemic studies are

needed.

The work was supported by the Ewha Global Top5 Grant 2013

of Ewha Womans University.

http://dx.doi.org/10.1016/j.ijom.2017.02.101

Recent advances inmolecular-targeted therapy for oral cancer

M. Kioi

Yokohama City University Graduate School of Medicine, Japan

Although the surgery is standard therapy for oral cancer in many

cases, advanced oral cancer is deadly and disfiguring disease for

which better systemic therapy is enormously sought to improve the

mortality and to avoid dysfunction and cosmetic disorder. Despite

recent advances in multimodality therapies for the treatment of

oral squamous cell carcinoma (OSCC), survival rates, functional

outcomes and toxicities of therapy remain poor.

The development of targeted therapies potentially decreased

toxicities and increased selectivity may represent significant

improvement for the efficacy and also as treatment options. Tar-

geted agents currently approved or under investigation for OSCC

include epidermal growth factor receptor (EGFR) monoclonal

antibodies, EGFR tyrosine kinase inhibitors, vascular endothelial

growth factor receptor inhibitors and various inhibitors of other

targets including immune-checkpoint.

In this talk, the recent advances in targeted therapy for OSCC

will be presented, and also our clinical outcome of several targeted

therapies using cetuximab and local therapy will be introduced.

http://dx.doi.org/10.1016/j.ijom.2017.02.102